Holen Sie sich die Stockscreener-App
16.51
4.68%
-0.81
Schlusskurs vom Vortag:
$17.32
Offen:
$17.27
24-Stunden-Volumen:
765.88K
Relative Volume:
0.87
Marktkapitalisierung:
$1.01B
Einnahmen:
$13.73M
Nettoeinkommen (Verlust:
$-114.48M
KGV:
-8.9641
EPS:
-1.8418
Netto-Cashflow:
$-78.49M
1W Leistung:
-10.22%
1M Leistung:
+1.63%
6M Leistung:
+8.69%
1J Leistung:
-39.30%
1-Tages-Spanne:
$16.43
$17.27
1-Wochen-Bereich:
$16.43
$18.61
52-Wochen-Spanne:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
Firmenname
Janux Therapeutics Inc
Sektor
Branche
Telefon
(858) 751-4493
Adresse
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
16.51 | 1.01B | 13.73M | -114.48M | -78.49M | -1.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-24 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2026-04-20 | Herabstufung | Barclays | Overweight → Underweight |
| 2026-04-15 | Herabstufung | UBS | Buy → Neutral |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-10 | Eingeleitet | Stifel | Buy |
| 2025-09-10 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-07-11 | Eingeleitet | Raymond James | Outperform |
| 2024-12-03 | Bestätigt | BTIG Research | Buy |
| 2024-12-03 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-05-30 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-03-21 | Eingeleitet | BTIG Research | Buy |
| 2024-03-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Eingeleitet | Wedbush | Outperform |
| 2022-11-14 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains? - Zacks Investment Research
Janux Therapeutics (NasdaqGM:JANX) Stock Forecast & Analyst Predictions - Simply Wall Street
The first patient gets Janux's new immune treatment in a prostate cancer trial. - Stock Titan
Price-Driven Insight from (JANX) for Rule-Based Strategy - Stock Traders Daily
Janux’s JANX014 Prostate Cancer Trial Advances, Keeping Early-Stage Upside in Play - TipRanks
Understanding the Setup: (JANX) and Scalable Risk - Stock Traders Daily
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44% - qz.com
Wolfe Research Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $23 - Moomoo
Wolfe Research upgrades Janux stock rating on autoimmune data By Investing.com - Investing.com Canada
Wolfe Research upgrades Janux stock rating on autoimmune data By Investing.com - Investing.com India
Wolfe Research upgrades Janux stock rating on autoimmune data By Investing.com - Investing.com UK
Wolfe Research upgrades Janux stock rating on autoimmune data - investing.com
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know - TradingView
Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile? - Sahm
Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile? - simplywall.st
Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile? - simplywall.st
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $14 to $60 - Moomoo
Janux (JANX) Latest Quarter: EPS Lands Above Forecast; Market Reaction: Shares Finish 3.30% Higher on the DayEstimate Revision Count - vinanet.vn
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Sprott (SII) Trading Review: Retreats 3.40% to $117.79 for the Current Session; Price Context: Traders Can Monitor the $111.90-$123.68 Range under the Current SnapshotBollinger Walk - careplusvn.com
Dimensional Fund Advisors LP Has $1.34 Million Stake in Janux Therapeutics, Inc. $JANX - MarketBeat
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Ginkgo Bioworks Holdings (DNA) - The Globe and Mail
Point72 reports 3.3% beneficial stake in Janux Therapeutics (JANX) via managed fund - stocktitan.net
Janus Henderson Group (JANX) reports 172,229 Janux Therapeutics shares under management - stocktitan.net
William Blair Maintains Janux Therapeutics(JANX.US) With Buy Rating - moomoo.com
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Janux Therapeutics (JANX) Gains 0.91% as Shares Firmly Hold Above $15.84 SupportHigh Conviction Picks - Vinanet
Equities Analysts Set Expectations for JANX Q3 Earnings - MarketBeat
HC Wainwright Has Negative Outlook of JANX FY2030 Earnings - MarketBeat
Why (JANX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile - Yahoo Finance
Janus Living Prices Share Offering - marketscreener.com
Janus Living Prices Share Offering - Moomoo
RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating - Moomoo
Analysts Have Lowered Expectations For Janux Therapeutics, Inc. (NASDAQ:JANX) After Its Latest Results - simplywall.st
RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating - marketscreener.com
Janux Therapeutics (NASDAQ:JANX) Announces Earnings Results - MarketBeat
Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX) - theglobeandmail.com
Janux Therapeutics Inc (JANX) Stock News Today - TradingKey
Janux Therapeutics Inc (JANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $33.25, Implies 107% Upside - TradingView
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - BioSpace
JANX Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline Drives FocusRevenue Guidance Update - vinanet.vn
Janux Therapeutics earnings missed by $0.08, revenue fell short of estimates - Investing.com Canada
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Janux Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Janux Therapeutics 2Q 2026: Revenue $10.3M, EPS $(0.35) — 10-Q Summary - TradingView
JANX: Clinical pipeline advanced and net loss narrowed, supported by nearly $1B in liquidity - TradingView
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q2 Revenue $10.3M, vs. FactSet Est of $19.1M - marketscreener.com
Finanzdaten der Janux Therapeutics Inc-Aktie (JANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Janux Therapeutics Inc-Aktie (JANX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr |
Jun 02 '26 |
Sale |
14.03 |
4,059 |
56,944 |
75,941 |
| Janeen Noel Doyle | Officer |
Jun 02 '26 |
Proposed Sale |
14.03 |
4,059 |
56,944 |
0 |
| Dobek Maria | Vice President, Accounting |
May 11 '26 |
Sale |
14.17 |
2,038 |
28,878 |
32,270 |
| ANDY MEYER | Former Affiliate |
Apr 13 '26 |
Proposed Sale |
15.05 |
1,877 |
28,246 |
0 |
| ZACHARIAH A MCIVER | Former Officer |
Apr 02 '26 |
Proposed Sale |
14.65 |
74,802 |
1,095,761 |
0 |
| ANDY MEYER | Former Affiliate |
Jan 26 '26 |
Proposed Sale |
14.55 |
178,767 |
2,601,113 |
0 |
| ANDY MEYER | Former Affiliate |
Jan 23 '26 |
Proposed Sale |
14.72 |
118,122 |
1,738,390 |
0 |
| Campbell David Alan | President and CEO |
Jan 02 '26 |
Sale |
13.73 |
8,072 |
110,829 |
284,982 |
| Winter Charles M. | Chief Technical Officer |
Jan 02 '26 |
Sale |
13.73 |
2,401 |
32,966 |
77,721 |
| McIver Zachariah | Chief Medical Officer |
Jan 02 '26 |
Sale |
13.73 |
2,714 |
37,263 |
23,286 |
3.96%
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):